Literature DB >> 15526176

[When is expensive pharmacotherapy good value for the money?].

A Riesberg1, M Velasco-Garrido, S Weinbrenner, C A Gericke, R Busse.   

Abstract

Expensive drugs are good value for money if they are effective and safe, and if they have a better cost-effectiveness ratio than the standard therapy. In this article, an overview of commonly used methods, sources and functions of health economic evaluation is presented and illustrated using clinical examples to facilitate interpretation of the health economic information.

Mesh：

Year:  2004        PMID： 15526176     DOI： 10.1007/s00108-004-1238-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  12 in total

1.  Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).

Authors:  B George; A Harris; A Mitchell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Best practice in undertaking and reporting health technology assessments. Working group 4 report.

Authors:  Marcial Velasco; Matthias Perleth; Michael Drummond; Felix Gürtner; Torben Jørgensen; Albert Jovell; Jim Malone; Alric Rüther; Claudia Wild
Journal:  Int J Technol Assess Health Care       Date:  2002       Impact factor: 2.188

3.  [Justice in health care systems from an economic perspective].

Authors:  J Schreyögg
Journal:  Gesundheitswesen       Date:  2004-01

4.  Alternative strategies for stroke care: cost-effectiveness and cost-utility analyses from a prospective randomized controlled trial.

Authors:  Anita Patel; Martin Knapp; Inigo Perez; Andrew Evans; Lalit Kalra
Journal:  Stroke       Date:  2003-12-18       Impact factor: 7.914

5.  Prehospital thrombolysis.

Authors:  Bernard D Prendergast
Journal:  BMJ       Date:  2003-07-05

6.  Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group.

Authors:  B J O'Brien; D Heyland; W S Richardson; M Levine; M F Drummond
Journal:  JAMA       Date:  1997-06-11       Impact factor: 56.272

7.  Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group.

Authors:  M F Drummond; W S Richardson; B J O'Brien; M Levine; D Heyland
Journal:  JAMA       Date:  1997-05-21       Impact factor: 56.272

8.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

9.  [Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients. Results of a controlled prospective study].

Authors:  C Krauth; R Busse; C Smaczny; G Ullrich; T O Wagner; J Weber; T Welte
Journal:  Med Klin (Munich)       Date:  1999-10-15

10.  Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns.

Authors:  J Ruof; G Klein; W März; H Wollschläger; A Neiss; M Wehling
Journal:  Prev Med       Date:  2002-07       Impact factor: 4.018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.